RESOLIAN Trademark

Trademark Overview


On Wednesday, February 15, 2023, a trademark application was filed for RESOLIAN with the United States Patent and Trademark Office. The USPTO has given the RESOLIAN trademark a serial number of 97796226. The federal status of this trademark filing is REGISTERED as of Tuesday, June 4, 2024. This trademark is owned by Alliance Pharma Inc.. The RESOLIAN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Laboratory testing services in clinical research and clinical trials of innovator and generic medicines in the pharmaceutical and biotechnology fields; Research and development in the fields of bioanalysis, immunoassay development, bioanalytical assay validation and testing, biomarker studies, drug metabolism, and pharmacokinetic testing; Pharmaceutical research and development services; Chemical, bioanalytical, biological and biotechnology research services; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Pharmaceutical drug development services; Scientific testing in the fields of oncology, neurology, gastroenterology, immunology, endocrinology, gene therapy, infectious disease, rare and orphan diseases, cardiovascular disease, metabolic disease, central nervous system, ophthalmology, and respiratory diseases, for medical and pharmaceutical research purposes; Drug and chemical materials analysis services, na...
resolian

General Information


Serial Number97796226
Word MarkRESOLIAN
Filing DateWednesday, February 15, 2023
Status700 - REGISTERED
Status DateTuesday, June 4, 2024
Registration Number7410177
Registration DateTuesday, June 4, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 9, 2024

Trademark Statements


Goods and ServicesLaboratory testing services in clinical research and clinical trials of innovator and generic medicines in the pharmaceutical and biotechnology fields; Research and development in the fields of bioanalysis, immunoassay development, bioanalytical assay validation and testing, biomarker studies, drug metabolism, and pharmacokinetic testing; Pharmaceutical research and development services; Chemical, bioanalytical, biological and biotechnology research services; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Pharmaceutical drug development services; Scientific testing in the fields of oncology, neurology, gastroenterology, immunology, endocrinology, gene therapy, infectious disease, rare and orphan diseases, cardiovascular disease, metabolic disease, central nervous system, ophthalmology, and respiratory diseases, for medical and pharmaceutical research purposes; Drug and chemical materials analysis services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmaceutical, biopharmaceutical, biotechnology and medical device development; Scientific analytical laboratory services; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of pharmaceutical drug, pharmaceutical excipient, and consumer healthcare chemical development; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of pharmaceutical drug, pharmaceutical excipient, and consumer healthcare chemical development; Analytical services, namely, providing Good Laboratory Practices (GLP) testing and quality assurance services to assess clinical performance in the field of therapeutic drug evaluation and development

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, March 6, 2023
Primary Code042
First Use Anywhere DateWednesday, May 17, 2023
First Use In Commerce DateWednesday, May 17, 2023

Trademark Owner History


Party NameAlliance Pharma Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355

Party NameAlliance Pharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355

Party NameAlliance Pharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355

Trademark Events


Event DateEvent Description
Monday, March 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, February 18, 2023NEW APPLICATION ENTERED
Tuesday, November 14, 2023ASSIGNED TO EXAMINER
Tuesday, November 14, 2023NON-FINAL ACTION WRITTEN
Tuesday, November 14, 2023NON-FINAL ACTION E-MAILED
Tuesday, November 14, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 28, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 28, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 29, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, December 2, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 20, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 9, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, April 1, 2024USE AMENDMENT FILED
Monday, April 1, 2024TEAS STATEMENT OF USE RECEIVED
Friday, April 19, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 19, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, April 30, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, April 30, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, June 4, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 4, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED